May Song, a doctor specializing in pharmaceutics, has extensive experience in researching and developing conventional and novel drug delivery systems. Her specialist interests revolve around pioneering pharmaceutical technologies, innovative drug dosage forms, and the evaluation of formulations in both in vitro & in vivo performance. She has successfully completed various projects, such as drug-controlled release systems, long-acting injections, cutting-edge taste-masking techniques for oral medications, and oral drug delivery systems aimed at enhancing bioavailability and drug stability. At the University of South Australia, she is actively engaged in multiple projects conducted at the Centre for Pharmaceutical Innovation, which... Read more
About me
May Song, a doctor specializing in pharmaceutics, has extensive experience in researching and developing conventional and novel drug delivery systems. Her specialist interests revolve around pioneering pharmaceutical technologies, innovative drug dosage forms, and the evaluation of formulations in both in vitro & in vivo performance. She has successfully completed various projects, such as drug-controlled release systems, long-acting injections, cutting-edge taste-masking techniques for oral medications, and oral drug delivery systems aimed at enhancing bioavailability and drug stability. At the University of South Australia, she is actively engaged in multiple projects conducted at the Centre for Pharmaceutical Innovation, which houses state-of-the-art pilot-scale pharmaceutical manufacturing facilities. She offers consultancy services to the industry, leads research and development initiatives, and mentors undergraduate and postgraduate students. Furthermore, she possesses extensive expertise in the management of a pharmaceutical laboratory.
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2018 |
Open access
3
|
2018 |
Open access
|
Year | Output |
---|---|
2024 |
Open access
7
8
3
|
2024 |
Open access
|
2024 |
Open access
1
1
|
2024 |
Open access
1
|
2024 |
Open access
2
2
114
|
2023 |
34
33
8
|
2023 |
Open access
2
2
218
|
2023 |
Open access
12
12
4
|
2023 |
Open access
7
6
2
|
2023 |
Open access
8
8
3
|
2023 |
Open access
1
1
|
2023 |
Open access
1
1
4
|
2023 |
Open access
9
8
1
|
2023 |
Open access
7
8
|
2023 |
Open access
|
2023 |
Open access
9
8
2
|
2022 |
Open access
14
13
6
|
2022 |
Open access
18
15
6
|
2022 |
Open access
10
9
4
|
2022 |
Open access
14
11
7
|
2022 |
Open access
4
4
4
|
2022 |
Open access
12
10
1
|
2022 |
Open access
80
75
2
|
2022 |
Open access
5
5
2
|
2022 |
Open access
7
6
1
|
2021 |
Open access
35
28
4
|
2021 |
Open access
57
49
6
|
2021 |
Open access
18
17
1
|
2021 |
Open access
6
7
|
2021 |
Open access
11
10
|
2021 |
Open access
11
11
|
2021 |
Open access
8
7
|
2021 |
Open access
25
23
1
|
2021 |
Open access
23
19
3
|
2021 |
Open access
19
18
1
|
2021 |
Open access
118
112
|
2020 |
Open access
16
16
|
2020 |
Open access
55
45
2
|
2020 |
Open access
10
9
1
|
2020 |
Open access
31
18
99
|
2020 |
Open access
5
4
1
|
2020 |
Open access
21
20
4
|
2020 |
Open access
1
1
|
2019 |
Open access
19
18
2
|
2019 |
Open access
9
9
2
|
2019 |
Open access
52
45
|
2019 |
Open access
42
37
|
2019 |
Open access
27
24
1
|
2019 |
Open access
24
23
3
|
2018 |
Open access
15
12
5
|
2018 |
38
36
|
2018 |
6
7
1
|
2018 |
Open access
15
13
1
|
2018 |
21
19
|
2018 |
38
30
81
|
2018 |
Open access
6
5
5
|
2018 |
Open access
17
15
1
|
2018 |
Open access
12
11
|
2017 |
4
4
|
2017 |
Open access
14
16
3
|
2017 |
Open access
1
1
1
|
2017 |
Open access
14
13
|
2017 |
Open access
9
9
1
|
2017 |
Open access
125
116
3
|
2017 |
Open access
10
10
|
2017 |
Open access
35
33
7
|
2017 |
Open access
18
17
|
2017 |
Open access
17
16
|
2016 |
Open access
27
25
|
2016 |
Open access
10
9
1
|
2016 |
77
74
4
|
2015 |
3
2
1
|
2015 |
Open access
39
34
|
2015 |
Open access
16
16
|
2015 |
Open access
7
7
|
2015 |
Open access
23
21
|
2011 |
Open access
40
38
|
2011 |
14
11
|
2011 |
Open access
79
69
|
2010 |
7
6
|
2010 |
86
64
|
2010 |
Open access
56
51
|
2009 |
102
92
|
2008 |
20
20
|
2008 |
50
40
|
Research
External engagement & recognition
Organisation | Country |
---|---|
Advanced Veterinary Therapeutics | AUSTRALIA |
Aix-Marseille University | FRANCE |
Chalmers University of Technology | SWEDEN |
China Pharmaceutical University | CHINA |
Chuulangun Aboriginal Corporation | AUSTRALIA |
Daping Hospital | CHINA |
Deakin University | AUSTRALIA |
Dermatology for Animals | AUSTRALIA |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
Fudan University | CHINA |
Kansas State University | UNITED STATES |
Luoda Pharma Pty Ltd | AUSTRALIA |
Monash University | AUSTRALIA |
Murdoch University | AUSTRALIA |
Neoculi Pty. Ltd. | AUSTRALIA |
Peking University | CHINA |
Royal Adelaide Hospital | AUSTRALIA |
Rush University | UNITED STATES |
SA Health | AUSTRALIA |
Shandong Provincial Qianfoshan Hospital | CHINA |
Shandong University | CHINA |
SunPork Group | AUSTRALIA |
The Queen Elizabeth Hospital | AUSTRALIA |
University of Adelaide | AUSTRALIA |
University of Bristol | UNITED KINGDOM |
University of California | UNITED STATES |
University of Canberra | AUSTRALIA |
University of Kansas | UNITED STATES |
University of Otago | NEW ZEALAND |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Western Australia | AUSTRALIA |
Vaxine Pty Ltd | AUSTRALIA |
Women's and Children's Hospital | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
MemberAustralasian Pharmaceutical Science Association (APSA) |
2018 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Artificial Intelligence-Driven 3D Printed Multi-layered Films for the Treatment of Glioblastoma | Current |
Development of a novel controlled release anticancer drugs combination system using 3D printing | Current |
Development of a novel controlled release anticancer drugs delivery system using 3D printing | Current |
Development of novel CBD drug delivery system for bioavailability improvement | Current |
Novel antimicrobials delivery systems for multi drug resistant infections | Current |
Novel topical delivery systems against resistant skin infections: acne and wound healing | Current |
3D printed biodegradable films for targeted chemotherapy in liver cancer | Completed |
Development of drug-eluting stents for the localised delivery of 5-fluorouracil targeted towards the treatment of gastrointestinal cancers | Completed |
Development of drug-eluting stents using dip-coating and 3D printing techniques for the localised treatment of oesophageal cancer | Completed |
Development of monocyte targeted delivery system for doxorubicin using modified inulin particles | Completed |
Development of novel micro-reservoir based buccal mucosal drug delivery systems | Completed |
Development of patient-centric conventional and 3D printed buccal films: enabling personalised medicine | Completed |
Evaluation of the role of pH in wound healing and development of buffered preparations to promote regeneration | Completed |
Innovative topical patches for the treatment of non-melanoma skin cancer | Completed |
Intracellular and localized drug delivery using inulin | Completed |
Novel functionalized mesoporous silica nanoparticles as targeted delivery systems to estrogen receptor-overexpressing breast cancer | Completed |
Three-dimensional printing of biodegradable polymeric scaffold for cancer therapy | Completed |